These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 12854284)

  • 1. [Male osteoporosis: current treatments and future options].
    Romagnoli E; Paglia F; Dionisi S; De Geronimo S; Pepe J; Di Virgilio R; Minisola S
    Clin Ter; 2003; 154(1):49-53. PubMed ID: 12854284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of parathyroid hormone as a therapy for osteoporosis.
    Rubin MR; Bilezikian JP
    Int J Fertil Womens Med; 2002; 47(3):103-15. PubMed ID: 12081255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
    De Nijs RN
    Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anabolic treatment for osteoporosis: PTH treatment].
    Kaji H; Sugimoto T
    Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoporosis: strategies for prevention and management.
    Keen R
    Best Pract Res Clin Rheumatol; 2007 Feb; 21(1):109-22. PubMed ID: 17350547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7: Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture.
    Seeman E; Eisman JA
    Med J Aust; 2004 Mar; 180(6):298-303. PubMed ID: 15012571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoid-induced osteoporosis.
    Berris KK; Repp AL; Kleerekoper M
    Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):446-50. PubMed ID: 17982350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GH and IGF-I as therapeutic agents for osteoporosis.
    Agnusdei D; Gentilella R
    J Endocrinol Invest; 2005; 28(8 Suppl):32-6. PubMed ID: 16323827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
    Martens MG
    J Reprod Med; 2003 Jun; 48(6):425-34. PubMed ID: 12856513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical review 123: Anabolic therapy for osteoporosis.
    Rosen CJ; Bilezikian JP
    J Clin Endocrinol Metab; 2001 Mar; 86(3):957-64. PubMed ID: 11238469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
    Epstein S
    Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevention and treatment of osteoporosis: a review.
    Cosman F
    MedGenMed; 2005 May; 7(2):73. PubMed ID: 16369451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current research in therapy of postmenopausal osteoporosis (author's transl)].
    Laroche C; Detilleux M; Sereni D
    Sem Hop; 1979 Feb 18-25; 55(7-8):325-9. PubMed ID: 220722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Past and future of anabolic agents.
    Ringe JD
    Ann Med Interne (Paris); 2000 Oct; 151(6):482-9. PubMed ID: 11104928
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of osteoporosis due to ovarian failure.
    Eastell R
    Med Pediatr Oncol; 2003 Sep; 41(3):222-7. PubMed ID: 12868123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Parathyroid hormone for osteroporsis: why and who to treat?].
    Ferrari S; Rizzoli R
    Rev Med Suisse; 2005 Oct; 1(35):2272-4, 2276-7. PubMed ID: 16268450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.